Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Health Catalyst, Inc.    HCAT

HEALTH CATALYST, INC.

(HCAT)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Health Catalyst Reports Third Quarter 2020 Results

11/10/2020 | 04:05pm EST

SALT LAKE CITY, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. (Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today reported financial results for the quarter ended September 30, 2020.

“In the third quarter of 2020, I am pleased to share that we achieved strong performance across our business, including exceeding the mid-point of our quarterly guidance for both revenue and Adjusted EBITDA,” said Dan Burton, CEO of Health Catalyst. “In addition to this financial and operational execution, we are excited to announce the promotion of Patrick Nelli, our current Chief Financial Officer, to the role President of Health Catalyst, effective January 1, 2021. Patrick's responsibilities as President will include all the major growth functions of the company, including with existing customers, new customers, international expansion, sales operations, marketing and communications. Additionally, I am pleased to announce the promotion of Bryan Hunt, our current Senior Vice President of Financial Planning & Analysis to the role of Chief Financial Officer, effective January 1, 2021. Patrick and Bryan, in their newly appointed roles, have my full support and confidence and the unanimous support and confidence of our board of directors. Lastly, I would also like to share two additional promotions related to these changes. Jason Alger, our Senior Vice President of Finance, has been promoted to Chief Accounting Officer, and Adam Brown, our Senior Vice President of Investor Relations, has been promoted to Senior Vice President of Investor Relations and Finance Planning & Analysis.”

Financial Highlights for the Three Months Ended September 30, 2020

Key Financial Metrics

 Three Months Ended
September 30,
 Year over Year Change
 2020 2019 
GAAP Financial Data:(in thousands, except percentages)
Technology revenue$27,964   $21,160   32%
Professional services revenue$19,227   $18,263   5%
Total revenue$47,191   $39,423   20%
Loss from operations$(23,458)  $(20,736)  (13)%
Net loss$(27,326)  $(21,416)  (28)%
Other Non-GAAP Financial Data:(1)     
Adjusted Technology Gross Profit$19,115   $14,484   32%
Adjusted Technology Gross Margin68 % 68 %  
Adjusted Professional Services Gross Profit$4,823   $6,677   (28)%
Adjusted Professional Services Gross Margin25 % 37 %  
Total Adjusted Gross Profit$23,938   $21,161   13%
Total Adjusted Gross Margin51 % 54 %  
Adjusted EBITDA$(6,434)  $(8,446)  24%

________________________
(1)  These measures are not calculated in accordance with generally accepted accounting principles in the United States (GAAP). See the accompanying "Non-GAAP Financial Measures" section below for more information about these financial measures, including the limitations of such measures, and for a reconciliation of each measure to the most directly comparable measure calculated in accordance with GAAP.

Financial Outlook

Health Catalyst provides forward-looking guidance on total revenue, a GAAP measure, and Adjusted EBITDA, a non-GAAP measure.

For the fourth quarter of 2020, we expect:

  • Total revenue between $50.5 million and $53.5 million, and
  • Adjusted EBITDA between $(7.3) million and $(5.3) million

For the full year of 2020, we expect:

  • Total revenue between $186.1 million and $189.1 million, and
  • Adjusted EBITDA between $(23.9) million and $(21.9) million

We have not reconciled guidance for Adjusted EBITDA to net loss, the most directly comparable GAAP measure, and have not provided forward-looking guidance for net loss, because there are items that may impact net loss, including stock-based compensation, that are not within our control or cannot be reasonably predicted.

Quarterly Conference Call Details

The company will host a conference call to review the results today, Tuesday, November 10, 2020 at 5:00 p.m. E.T. The conference call can be accessed by dialing 1-877-295-1104 for U.S. participants, or 1-470-495-9486 for international participants, and referencing participant code 7195951. A live audio webcast will be available online at https://ir.healthcatalyst.com/. A replay of the call will be available via webcast for on-demand listening shortly after the completion of the call, at the same web link, and will remain available for approximately 90 days.

About Health Catalyst

Health Catalyst is a leading provider of data and analytics technology and services to healthcare organizations committed to being the catalyst for massive, measurable, data-informed healthcare improvement. Its customers leverage the cloud-based data platform—powered by data from more than 100 million patient records and encompassing trillions of facts—as well as its analytics software and professional services expertise to make data-informed decisions and realize measurable clinical, financial, and operational improvements. Health Catalyst envisions a future in which all healthcare decisions are data informed.

Available Information

Health Catalyst intends to use its Investor Relations website as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD.

Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, as amended. These forward-looking statements include statements regarding our future growth and our financial outlook for Q4 and fiscal year 2020. Forward-looking statements are subject to risks and uncertainties and are based on potentially inaccurate assumptions that could cause actual results to differ materially from those expected or implied by the forward-looking statements. Actual results may differ materially from the results predicted, and reported results should not be considered as an indication of future performance.

Important risks and uncertainties that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: (i) changes in laws and regulations applicable to our business model; (ii) changes in market or industry conditions, regulatory environment and receptivity to our technology and services; (iii) results of litigation or a security incident; (iv) the loss of one or more key customers or partners; (v) the impact of COVID-19 on our business and results of operation; and (vi) changes to our abilities to recruit and retain qualified team members. For a detailed discussion of the risk factors that could affect our actual results, please refer to the risk factors identified in our SEC reports, including, but not limited to the Annual Report on Form 10-K for the year ended December 31, 2019 filed with the SEC on February 28, 2020 and the Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2020 expected to be filed with the SEC on or about November 10, 2020.  All information provided in this release and in the attachments is as of the date hereof, and we undertake no duty to update or revise this information unless required by law.

 
Condensed Consolidated Balance Sheets
(in thousands, except share and per share data, unaudited)
 
 As of
September 30,
 As of
December 31,
 2020 2019
Assets   
Current assets:   
Cash and cash equivalents$111,239  $18,032 
Short-term investments163,898  210,245 
Accounts receivable, net36,339  27,570 
Prepaid expenses and other assets11,290  8,392 
Total current assets322,766  264,239 
Property and equipment, net5,319  4,295 
Intangible assets, net105,926  25,535 
Operating lease right-of-use assets25,833  3,787 
Goodwill107,822  3,694 
Other assets2,997  810 
Total assets$570,663  $302,360 
Liabilities and stockholders’ equity   
Current liabilities:   
Accounts payable$5,189  $3,622 
Accrued liabilities14,061  8,944 
Acquisition-related consideration payable3,214  2,192 
Deferred revenue35,090  30,653 
Operating lease liabilities2,425  2,806 
Contingent consideration liabilities5,893   
Total current liabilities65,872  48,217 
Long-term debt, net of current portion166,200  48,200 
Acquisition-related consideration payable, net of current portion  1,860 
Deferred revenue, net of current portion1,635  1,459 
Operating lease liabilities, net of current portion24,245  1,654 
Contingent consideration liabilities, net of current portion10,279   
Other liabilities2,817  326 
Total liabilities271,048  101,716 
Commitments and contingencies   
Stockholders’ equity:   
Common stock, $0.001 par value; 42,239,922 and 36,678,854 shares issued and outstanding as
 of September 30, 2020 and December 31, 2019, respectively
42  37 
Additional paid-in capital982,139  811,049 
Accumulated deficit(682,632) (610,514)
Accumulated other comprehensive income66  72 
Total stockholders' equity299,615  200,644 
Total liabilities and stockholders’ equity$570,663  $302,360 
        



 
Condensed Consolidated Statements of Operations
(in thousands, except per share data, unaudited)
 
 Three Months Ended
September 30,
 Nine Months Ended
September 30,
 2020 2019 2020 2019
Revenue:       
Technology$27,964  $21,160  $78,150  $61,393 
Professional services19,227  18,263  57,416  50,047 
Total revenue47,191  39,423  135,566  111,440 
Cost of revenue, excluding depreciation and amortization:       
Technology(1)9,045  6,740  25,148  20,536 
Professional services(1)(3)15,307  11,892  46,401  33,132 
Total cost of revenue, excluding depreciation and amortization24,352  18,632  71,549  53,668 
Operating expenses:       
Sales and marketing(1)(3)14,629  14,721  40,618  35,579 
Research and development(1)(3)13,390  13,477  38,539  33,209 
General and administrative(1)(2)(4)(5)13,297  11,013  31,111  23,333 
Depreciation and amortization4,981  2,316  10,952  6,844 
Total operating expenses46,297  41,527  121,220  98,965 
Loss from operations(23,458) (20,736) (57,203) (41,193)
Loss on extinguishment of debt    (8,514) (1,670)
Interest and other expense, net(3,854) (659) (7,500) (2,924)
Loss before income taxes(27,312) (21,395) (73,217) (45,787)
Income tax provision (benefit)14  21  (1,218) 43 
Net loss$(27,326) $(21,416) $(71,999) $(45,830)
Less: accretion of redeemable convertible preferred stock  18,170    180,826 
Net loss attributable to common stockholders$(27,326) $(39,586) $(71,999) $(226,656)
Net loss per share attributable to common stockholders, basic and diluted$(0.68) $(1.40) $(1.87) $(17.78)
Weighted-average shares outstanding used in calculating net
 loss per share attributable to common stockholders, basic and diluted
40,292  28,223  38,517  12,750 
Adjusted net loss(6)$(8,287) $(9,817) $(20,110) $(26,014)
Pro forma adjusted net loss per share, basic and diluted(6)$(0.21) $(0.27) $(0.52) $(0.72)
Pro forma as adjusted weighted-average number of shares
 outstanding used in calculating Adjusted Net Loss per share, basic and diluted(6)
40,292  36,373  38,517  36,183 

_______________

(1)  Includes stock-based compensation expense as follows:

 Three Months Ended
September 30,
 Nine Months Ended
September 30,
 2020 2019 2020 2019
Stock-Based Compensation Expense:(in thousands) (in thousands)
Cost of revenue, excluding depreciation and amortization:       
Technology$196 $64 $575 $129
Professional services903 306 2,609 593
Sales and marketing3,233 1,358 9,724 2,639
Research and development2,025 3,067 5,987 3,502
General and administrative3,139 5,179 8,388 6,165
Total$9,496 $9,974 $27,283 $13,028

(2)   Includes acquisition transaction costs as follows:

 Three Months Ended
September 30,
 Nine Months Ended
September 30,
 2020 2019 2020 2019
Acquisition transaction costs:(in thousands) (in thousands)
General and administrative$1,399 $ $2,670 $
Total$1,399 $ $2,670 $

(3)   Includes post-acquisition restructuring costs as follows:

 Three Months Ended
September 30,
 Nine Months Ended
September 30,
 2020 2019 2020 2019
Post-Acquisition Restructuring Costs:(in thousands) (in thousands)
Cost of revenue, excluding depreciation and amortization:       
Professional services$ $ $ $108
Sales and marketing   306
Research and development   32
Total$ $ $ $446

(4)   Includes the change in fair value of contingent consideration liabilities, as follows:

 Three Months Ended
September 30,
 Nine Months Ended
September 30,
 2020 2019 2020 2019
Change in fair value of contingent consideration liabilities:(in thousands) (in thousands)
General and administrative$564 $ $(1,004) $
Total$564 $ $(1,004) $

(5)   Includes duplicate headquarters rent expense, as follows:

 Three Months Ended
September 30,
 Nine Months Ended
September 30,
 2020 2019 2020 2019
Duplicate Headquarters Rent Expense:(in thousands) (in thousands)
General and administrative$584 $ $709 $
Total$584 $ $709 $

(6)   Includes pro forma adjustments to net loss attributable to common stockholders and the weighted average number of common shares outstanding directly attributable to the closing of our initial public offering on July 29, 2019 as well as certain other non-GAAP adjustments. Refer to the "Non-GAAP Financial Measures—Pro Forma Adjusted Net Loss Per Share" section below for further details.

 
Condensed Consolidated Statements of Cash Flows
(in thousands, unaudited)
 
 Nine Months Ended
September 30,
Cash flows from operating activities2020 2019
Net loss$(71,999) $(45,830)
Adjustments to reconcile net loss to net cash used in operating activities:   
Depreciation and amortization10,952  6,844 
Loss on extinguishment of debt8,514  1,670 
Amortization of debt discount and issuance costs5,260  797 
Non-cash operating lease expense2,865  2,696 
Investment discount and premium amortization854  (443)
Provision for expected credit losses822   
Stock-based compensation expense27,283  13,028 
Deferred tax (benefit) provision(1,280)  
Change in fair value of contingent consideration liabilities(1,004)  
Other85  (36)
Change in operating assets and liabilities:   
Accounts receivable, net(4,450) (3,323)
Prepaid expenses and other assets(2,937) (1,362)
Accounts payable, accrued liabilities, and other liabilities6,567  1,661 
Deferred revenue(838) 7,601 
Operating lease liabilities(2,701) (2,426)
Net cash used in operating activities(22,007) (19,123)
    
Cash flows from investing activities   
Purchase of short-term investments(163,346) (221,444)
Proceeds from the sale and maturity of short-term investments208,467  37,277 
Acquisition of businesses, net of cash acquired(102,471)  
Purchase of property and equipment(2,071) (1,658)
Purchase of intangible assets(1,249) (1,747)
Proceeds from sale of property and equipment10  40 
Net cash used in investing activities(60,660) (187,532)
    
Cash flows from financing activities   
Proceeds from convertible note securities, net of issuance costs222,482   
Purchase of capped calls concurrent with issuance of convertible senior notes(21,743)  
Proceeds from credit facilities, net of debt issuance costs  47,169 
Repayment of credit facilities(57,043) (21,821)
Proceeds from exercise of stock options29,393  2,177 
Proceeds from employee stock purchase plan3,528  1,216 
Payments of acquisition-related consideration(748) (773)
Proceeds from initial public offering, net of underwriters’ discounts and commissions  194,649 
Proceeds from the issuance of redeemable convertible preferred stock, net of issuance costs  12,073 
Payments of deferred offering costs  (4,407)
Net cash provided by financing activities175,869  230,283 
Effect of exchange rate on cash and cash equivalents5   
Net increase in cash and cash equivalents93,207  23,628 
    
Cash and cash equivalents at beginning of period18,032  28,431 
Cash and cash equivalents at end of period$111,239  $52,059 
        

Non-GAAP Financial Measures

To supplement our financial information presented in accordance with GAAP, we believe certain non-GAAP measures, including Adjusted Gross Profit, Adjusted Gross Margin, Adjusted EBITDA, Adjusted Net Loss, and Adjusted Net Loss per share, basic and diluted, are useful in evaluating our operating performance. We use this non-GAAP financial information to evaluate our ongoing operations, as a component in determining employee bonus compensation, and for internal planning and forecasting purposes. We believe that non-GAAP financial information, when taken collectively, may be helpful to investors because it provides consistency and comparability with past financial performance. However, non-GAAP financial information is presented for supplemental informational purposes only, has limitations as an analytical tool and should not be considered in isolation or as a substitute for financial information presented in accordance with GAAP. In addition, other companies, including companies in our industry, may calculate similarly-titled non-GAAP measures differently or may use other measures to evaluate their performance. A reconciliation is provided below for each non-GAAP financial measure to the most directly comparable financial measure stated in accordance with GAAP. Investors are encouraged to review the related GAAP financial measures and the reconciliation of these non-GAAP financial measures to their most directly comparable GAAP financial measures, and not to rely on any single financial measure to evaluate our business.

Adjusted Gross Profit and Adjusted Gross Margin

Adjusted Gross Profit is a non-GAAP financial measure that we define as revenue less cost of revenue, excluding depreciation and amortization and excluding (i) stock-based compensation and (ii) post-acquisition restructuring costs (none during periods presented). We define Adjusted Gross Margin as our Adjusted Gross Profit divided by our revenue. We believe Adjusted Gross Profit and Adjusted Gross Margin are useful to investors as they eliminate the impact of certain non-cash expenses and allow a direct comparison of these measures between periods without the impact of non-cash expenses and certain other non-recurring operating expenses. The following is a reconciliation of revenue, the most directly comparable GAAP financial measure, to Adjusted Gross Profit, for the three months ended September 30, 2020 and 2019:

 Three Months Ended September 30, 2020
 (in thousands, except percentages)
 Technology Professional Services Total
Revenue$27,964   $19,227   $47,191  
Cost of revenue, excluding depreciation and amortization(9,045)  (15,307)  (24,352) 
Gross profit, excluding depreciation and amortization18,919   3,920   22,839  
Add:     
Stock-based compensation196   903   1,099  
Adjusted Gross Profit$19,115   $4,823   $23,938  
Gross margin, excluding depreciation and amortization68 % 20 % 48 %
Adjusted Gross Margin68 % 25 % 51 %


 Three Months Ended September 30, 2019
 (in thousands, except percentages)
 Technology Professional Services Total
Revenue$21,160   $18,263   $39,423  
Cost of revenue, excluding depreciation and amortization(6,740)  (11,892)  (18,632) 
Gross profit, excluding depreciation and amortization14,420   6,371   20,791  
Add:     
Stock-based compensation64   306   370  
Adjusted Gross Profit$14,484   $6,677   $21,161  
Gross margin, excluding depreciation and amortization68 % 35 % 53 %
Adjusted Gross Margin68 % 37 % 54 %
            

Adjusted EBITDA

Adjusted EBITDA is a non-GAAP financial measure that we define as net loss adjusted for (i) interest and other expense, net, (ii) loss on extinguishment of debt (none in periods presented), (iii) income tax (benefit) provision, (iv) depreciation and amortization, (v) stock-based compensation, (vi) acquisition transaction costs, (vii) change in fair value of contingent consideration liability, (viii) duplicate headquarters rent expense, and (ix) post-acquisition restructuring costs when they are incurred. We believe Adjusted EBITDA provides investors with useful information on period-to-period performance as evaluated by management and comparison with our past financial performance and is useful in evaluating our operating performance compared to that of other companies in our industry, as this metric generally eliminates the effects of certain items that may vary from company to company for reasons unrelated to overall operating performance. The following is a reconciliation of our net loss, the most directly comparable GAAP financial measure, to Adjusted EBITDA, for the three months ended September 30, 2020 and 2019:

 Three Months Ended
September 30,
 2020 2019
 (in thousands)
Net loss$(27,326) $(21,416)
Add:   
Interest and other expense, net3,854  659 
Income tax (benefit) provision14  21 
Depreciation and amortization4,981  2,316 
Stock-based compensation9,496  9,974 
Acquisition transaction costs1,399   
Change in fair value of contingent consideration liability564   
Duplicate headquarters rent expense584   
Adjusted EBITDA$(6,434) $(8,446)
        

Pro Forma Adjusted Net Loss Per Share

Adjusted Net Loss is a non-GAAP financial measure that we define as net loss attributable to common stockholders adjusted for (i) accretion of redeemable convertible preferred stock, (ii) stock-based compensation, (iii) amortization of acquired intangibles, (iv) loss on debt extinguishment, (v) acquisition transaction costs, (vi) change in fair value of contingent consideration liability, (vii) non-cash interest expense related to our convertible senior notes, (viii) duplicate headquarters rent expense (see explanation above), and (ix) post-acquisition restructuring costs. Non-cash interest expense related to our convertible senior notes relates to the convertible senior notes that were issued in a private placement in April 2020. Under GAAP, we are required to separately account for liability (debt) and equity (conversion option) components of the convertible senior notes. Accordingly, for GAAP purposes we are required to recognize the effective interest expense on our convertible senior notes and amortize the issuance costs over the term of the notes. The difference between the effective interest expense and the contractual interest expense, and the amortization expense of issuance costs are excluded from management’s assessment of our operating performance because management believes that these non-cash expenses are not indicative of ongoing operating performance.We believe Adjusted Net Loss provides investors with useful information on period-to-period performance as evaluated by management and comparison with our past financial performance and is useful in evaluating our operating performance compared to that of other companies in our industry, as this metric generally eliminates the effects of certain items that may vary from company to company for reasons unrelated to overall operating performance.

On July 29, 2019, we closed our initial public offering (our IPO) in which we issued and sold 8,050,000 shares (inclusive of the underwriters’ option to purchase an additional 1,050,000 shares) of common stock at $26.00 per share. We received net proceeds of $194.6 million after deducting underwriting discounts and commissions and before deducting offering costs of $4.6 million. Upon the closing of our IPO, all shares of our outstanding redeemable convertible preferred stock converted into 23,151,481 shares of common stock on a one-for-one basis. We have prepared the below adjusted condensed consolidated statement of operations data to present pro forma adjusted net loss per share amounts that will be comparable between the current and prior periods presented as if the conversion of all outstanding shares of redeemable convertible preferred stock and the issuance of the IPO shares had occurred as of the beginning of the prior year comparative periods.

 Three Months Ended September 30, Nine Months Ended September 30,
 2020 2019 2020 2019
Numerator:(in thousands, except share and per share amounts)
Net loss attributable to common stockholders$(27,326) $(39,586) $(71,999) $(226,656)
Add       
Accretion of redeemable convertible preferred stock  18,170    180,826 
Stock-based compensation9,496  9,974  27,283  13,028 
Amortization of acquired intangibles4,276  1,625  8,786  4,672 
Loss on extinguishment of debt    8,514  1,670 
Acquisition transaction costs1,399    2,670   
Change in fair value of contingent consideration liability564    (1,004)  
Non-cash interest expense related to convertible senior notes2,720    4,931   
Duplicate headquarters rent expense584    709   
Post-acquisition restructuring costs      446 
Adjusted Net Loss$(8,287) $(9,817) $(20,110) $(26,014)
Denominator:       
Weighted-average number of shares used in
 calculating net loss per share attributable to
 common stockholders, basic and diluted
40,292,380  28,222,555  38,517,272  12,749,903 
Pro forma adjustments       
Pro forma adjustment to reflect issuance and
 conversion of redeemable convertible
 preferred stock to common stock, assuming
 the conversion took place as of
 the beginning of the 2019 period
  6,039,517    17,384,812 
Pro forma adjustment to reflect issuance of
 shares of common stock as part of IPO,
 assuming the issuance took place as of the
 beginning of the 2019 period
  2,111,413    6,048,718 
Pro forma as adjusted weighted-average
 number of shares used in calculating
 Adjusted Net Loss per share, basic and diluted
40,292,380  36,373,485  38,517,272  36,183,433 
Pro forma adjusted net loss per share, basic and diluted$(0.21) $(0.27) $(0.52) $(0.72)


Health Catalyst Investor Relations Contact:
Adam Brown
Senior Vice President, Investor Relations
+1 (855)-309-6800
ir@healthcatalyst.com

Health Catalyst Media Contact:
Amanda Hundt
amanda.hundt@healthcatalyst.com
+1 (575) 491-0974

Primary Logo


© GlobeNewswire 2020
All news about HEALTH CATALYST, INC.
01/26HEALTH CATALYST : How Activity-Based Costing Can Boost Hospital Finances (Becker..
PU
01/26HEALTH CATALYST : Business Elevated Podcast Interview with Dan Orentstein (Utah ..
PU
01/19BUSINESS RADIO X : Trudy Sullivan Interview
PU
01/18HEALTH CATALYST : Becker's Healthcare CEO + CFO Forum
PU
01/13HEALTH CATALYST : Named a Glassdoor Best Places to Work for the Fourth Time in S..
PU
01/13HEALTH CATALYST : Re-Certified as a Great Place to Work Company
PU
01/07HEALTH CATALYST : Data Bridge the Knowledge Gaps in the Fight Against COVID-19
PU
01/07TRANSFORMATION CAPITAL : Launches $500 Million Digital Health Fund to Support En..
PR
2020Health Catalyst to Participate in Upcoming Investor Conference
GL
2020HEALTH CATALYST : Utah Companies Recognized for Leadership, Training and Creativ..
PU
More news
Financials (USD)
Sales 2020 188 M - -
Net income 2020 -91,8 M - -
Net cash 2020 96,9 M - -
P/E ratio 2020 -21,5x
Yield 2020 -
Capitalization 2 188 M 2 188 M -
EV / Sales 2020 11,1x
EV / Sales 2021 9,34x
Nbr of Employees 1 000
Free-Float 95,1%
Chart HEALTH CATALYST, INC.
Duration : Period :
Health Catalyst, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends HEALTH CATALYST, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 14
Average target price 45,92 $
Last Close Price 51,49 $
Spread / Highest target 12,6%
Spread / Average Target -10,8%
Spread / Lowest Target -28,1%
EPS Revisions
Managers and Directors
NameTitle
Daniel D. Burton Chief Executive Officer & Director
Patrick J. Nelli President
Paul Horstmeier Chief Operating Officer
Bryan Hunt Chief Financial Officer
Holly Rimmasch Chief Clinical Officer
Sector and Competitors
1st jan.Capitalization (M$)
HEALTH CATALYST, INC.18.29%2 188
THERMO FISHER SCIENTIFIC9.03%201 271
DANAHER CORPORATION0.03%166 214
INTUITIVE SURGICAL, INC.-7.26%90 477
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.14.55%85 238
ILLUMINA, INC.16.84%61 400